CluenexRoyalty Pharma RPRX
Royalty Pharma scores average on business quality (4.7 of 10). Here is why, in plain words, and what our sealed record shows.
Why it matters
- What Royalty Pharma does
Royalty Pharma buys and holds income streams from 16 blockbuster drugs, funding clinical trials in exchange for a percentage of future drug sales paid by major pharmaceutical companies. The firm is expanding its funding footprint across clinical-stage pipelines to secure future royalty streams.
- What it does best
Royalty Pharma secures elite pharmaceutical royalty streams with an operating margin of 62%, beating peers like Merck at 16%. This scale creates high barriers as developers trade future risk for upfront capital.
- The main risk
Net debt has climbed to $8.3B with an interest coverage ratio of 4.4x, leaving narrow room if acquired drug revenue misses expectations.
Quality, check by check
Scored against its own industry, from company filings.
Operating margin hits 62% driven by low overhead costs, though profitability relies entirely on partner drug sales performance.
The business model locks in biopharma developers via upfront capital, ranking in the top decile for sector operating margin.
Revenue grew 5.0% to $2.5B, showing mild acceleration compared to flat periods in recent annual history.
Total debt sits at $9.0B against $637M in cash, while free cash flow dropped to $577M, leaving the balance sheet softer.
Insiders
Executives and directors, from SEC Form 4 filings we read ourselves. Open market trades only; grants, option exercises and pre-planned sales left out.
No open market buys or unplanned sales by executives or directors.
Our sealed record on RPRX
Verdicts appear here 30 days after we publish them; members see today's. Each one is in the nightly ledger, fingerprinted the night it was made.
The first sealed verdicts appear here on Oct 11, 2026.
Questions
Royalty Pharma scores average on the Cluenex quality check (4.7 of 10), measured against its own industry. Profitability is strong, moat fair, growth slow and financial health weak.
In the last 90 days of SEC Form 4 filings: No open market buys or unplanned sales by executives or directors.
Nov 4, 2026.
See RPRX today
- Today's verdict on RPRX, and why
- Fair value with cautious, base and optimistic cases
- The exact price that would change the verdict
- Which stocks each signal names, the night it fires
Cite this page: Cluenex, “Royalty Pharma (RPRX)”, https://cluenex.com/stocks/rprx/, data as of Oct 10, 2026.